| Year |
Citation |
Score |
| 2020 |
Noack AK, Lucas H, Chytil P, Etrych T, Mäder K, Mueller T. Intratumoral Distribution and pH-Dependent Drug Release of High Molecular Weight HPMA Copolymer Drug Conjugates Strongly Depend on Specific Tumor Substructure and Microenvironment. International Journal of Molecular Sciences. 21. PMID 32825790 DOI: 10.3390/ijms21176029 |
0.546 |
|
| 2020 |
Filipová M, Bojarová P, Rodrigues Tavares M, Bumba L, Elling L, Chytil P, Gunár K, Křen V, Etrych T, Janoušková O. Glycopolymers for Efficient Inhibition of Galectin-3: Proof of Efficacy Using Suppression of T Lymphocyte Apoptosis and Tumor Cell Migration. Biomacromolecules. PMID 32697592 DOI: 10.1021/acs.biomac.0c00515 |
0.302 |
|
| 2020 |
Randárová E, Nakamura H, Islam R, Studenovský M, Mamoru H, Fang J, Chytil P, Etrych T. Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization. Acta Biomaterialia. PMID 32058082 DOI: 10.1016/j.actbio.2020.02.011 |
0.577 |
|
| 2020 |
Janisova L, Gruzinov A, Zaborova OV, Velychkivska N, Vaněk O, Chytil P, Etrych T, Janoušková O, Zhang X, Blanchet C, Papadakis CM, Svergun DI, Filippov SK. Molecular Mechanisms of the Interactions of -(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins. Pharmaceutics. 12. PMID 32013056 DOI: 10.3390/pharmaceutics12020106 |
0.308 |
|
| 2019 |
Nakamura H, Koziolová E, Chytil P, Etrych T, Haratake M, Maeda H. Superior Penetration and Cytotoxicity of HPMA Copolymer Conjugates of Pirarubicin in Tumor Cell Spheroid. Molecular Pharmaceutics. PMID 31294568 DOI: 10.1021/acs.molpharmaceut.9b00248 |
0.34 |
|
| 2019 |
Lynn GM, Chytil P, Francica JR, Lagova A, Kueberuwa G, Ishizuka AS, Zaidi N, Ramirez-Valdez RA, Blobel NJ, Baharom F, Leal J, Wang AQ, Gerner MY, Etrych T, Ulbrich K, et al. Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and mechanism of CD8 T cell induction. Biomacromolecules. PMID 30608149 DOI: 10.1021/Acs.Biomac.8B01473 |
0.57 |
|
| 2018 |
Chytil P, Šírová M, Kudláčová J, Říhová B, Ulbrich K, Etrych T. Bloodstream Stability Predetermines the Antitumor Efficacy of Micellar Polymer-Doxorubicin Drug Conjugates with pH-Triggered Drug Release. Molecular Pharmaceutics. 15: 3654-3663. PMID 29543465 DOI: 10.1021/acs.molpharmaceut.8b00156 |
0.768 |
|
| 2018 |
Zhang X, Niebuur BJ, Chytil P, Etrych T, Filippov SK, Kikhney A, Wieland DCF, Svergun DI, Papadakis CM. Macromolecular pHPMA-Based Nanoparticles with Cholesterol for Solid Tumor Targeting: Behavior in HSA Protein Environment. Biomacromolecules. PMID 29381335 DOI: 10.1021/acs.biomac.7b01579 |
0.368 |
|
| 2017 |
Weiss VM, Lucas H, Mueller T, Chytil P, Etrych T, Naolou T, Kressler J, Mäder K. Intended and Unintended Targeting of Polymeric Nanocarriers: The Case of Modified Poly(glycerol adipate) Nanoparticles. Macromolecular Bioscience. PMID 29218838 DOI: 10.1002/mabi.201700240 |
0.323 |
|
| 2017 |
Islam W, Fang J, Etrych T, Chytil P, Ulbrich K, Sakoguchi A, Kusakabe K, Maeda H. HPMA Copolymer Conjugate with Pirarubicin: In Vitro and Ex Vivo Stability and Drug Release study. International Journal of Pharmaceutics. PMID 29133205 DOI: 10.1016/j.ijpharm.2017.11.011 |
0.678 |
|
| 2017 |
Chytil P, Koziolová E, Etrych T, Ulbrich K. HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release. Macromolecular Bioscience. 18. PMID 28805040 DOI: 10.1002/mabi.201700209 |
0.741 |
|
| 2017 |
Koziolová E, Goel S, Chytil P, Janoušková O, Barnhart TE, Cai W, Etrych T. A tumor-targeted polymer theranostics platform for positron emission tomography and fluorescence imaging. Nanoscale. PMID 28731080 DOI: 10.1039/C7Nr03306K |
0.461 |
|
| 2017 |
Etrych T, Tsukigawa K, Nakamura H, Chytil P, Fang J, Ulbrich K, Otagiri M, Maeda H. Comparison of the pharmacological and biological properties of HPMA copolymer-pirarubicin conjugates: A single-chain copolymer conjugate and its biodegradable tandem-diblock copolymer conjugate. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. PMID 28528285 DOI: 10.1016/j.ejps.2017.05.031 |
0.667 |
|
| 2016 |
Nakamura H, Koziolová E, Chytil P, Tsukigawa K, Fang J, Haratake M, Ulbrich K, Etrych T, Maeda H. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin. Molecular Pharmaceutics. 13: 4106-4115. PMID 27934482 DOI: 10.1021/acs.molpharmaceut.6b00697 |
0.74 |
|
| 2016 |
Lomkova EA, Chytil P, Janoušková O, Mueller T, Lucas H, Filippov SK, Trhlíková O, Aleshunin PA, Skorik YA, Ulbrich K, Etrych T. Biodegradable micellar HPMA-based polymer-drug conjugates with betulinic acid for passive tumor targeting. Biomacromolecules. PMID 27636143 DOI: 10.1021/acs.biomac.6b00947 |
0.75 |
|
| 2016 |
Heinrich AK, Lucas H, Schindler L, Chytil P, Etrych T, Mäder K, Mueller T. Improved tumor specific drug accumulation by polymer therapeutics with pH-sensitive drug release overcomes chemotherapy resistance. Molecular Cancer Therapeutics. PMID 26939698 DOI: 10.1158/1535-7163.MCT-15-0824 |
0.507 |
|
| 2015 |
Tomalova B, Sirova M, Rossmann P, Pola R, Strohalm J, Chytil P, Cerny V, Tomala J, Kabesova M, Rihova B, Ulbrich K, Etrych T, Kovar M. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia. Journal of Controlled Release : Official Journal of the Controlled Release Society. 223: 1-10. PMID 26708020 DOI: 10.1016/j.jconrel.2015.12.023 |
0.708 |
|
| 2015 |
Dozono H, Yanazume S, Nakamura H, Etrych T, Chytil P, Ulbrich K, Fang J, Arimura T, Douchi T, Kobayashi H, Ikoma M, Maeda H. HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases. Targeted Oncology. PMID 26194363 DOI: 10.1007/s11523-015-0379-4 |
0.58 |
|
| 2015 |
Chytil P, Koziolová E, Janoušková O, Kostka L, Ulbrich K, Etrych T. Synthesis and Properties of Star HPMA Copolymer Nanocarriers Synthesised by RAFT Polymerisation Designed for Selective Anticancer Drug Delivery and Imaging. Macromolecular Bioscience. 15: 839-50. PMID 25731143 DOI: 10.1002/mabi.201400510 |
0.706 |
|
| 2015 |
Nakamura H, Koziolová E, Etrych T, Chytil P, Fang J, Ulbrich K, Maeda H. Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 90: 90-6. PMID 25460144 DOI: 10.1016/j.ejpb.2014.10.007 |
0.64 |
|
| 2014 |
Nakamura H, Etrych T, Chytil P, Ohkubo M, Fang J, Ulbrich K, Maeda H. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. Journal of Controlled Release : Official Journal of the Controlled Release Society. 174: 81-7. PMID 24269967 DOI: 10.1016/j.jconrel.2013.11.011 |
0.689 |
|
| 2013 |
Filippov SK, Franklin JM, Konarev PV, Chytil P, Etrych T, Bogomolova A, Dyakonova M, Papadakis CM, Radulescu A, Ulbrich K, Stepanek P, Svergun DI. Hydrolytically degradable polymer micelles for drug delivery: a SAXS/SANS kinetic study. Biomacromolecules. 14: 4061-70. PMID 24083567 DOI: 10.1021/bm401186z |
0.704 |
|
| 2013 |
Chytil P, Hoffmann S, Schindler L, Kostka L, Ulbrich K, Caysa H, Mueller T, Mäder K, Etrych T. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution. Journal of Controlled Release : Official Journal of the Controlled Release Society. 172: 504-12. PMID 23697767 DOI: 10.1016/j.jconrel.2013.05.008 |
0.748 |
|
| 2013 |
Jäger E, Jäger A, Chytil P, Etrych T, Ríhová B, Giacomelli FC, Stěpánek P, Ulbrich K. Combination chemotherapy using core-shell nanoparticles through the self-assembly of HPMA-based copolymers and degradable polyester. Journal of Controlled Release : Official Journal of the Controlled Release Society. 165: 153-61. PMID 23178950 DOI: 10.1016/j.jconrel.2012.11.009 |
0.643 |
|
| 2012 |
Filippov SK, Chytil P, Konarev PV, Dyakonova M, Papadakis C, Zhigunov A, Plestil J, Stepanek P, Etrych T, Ulbrich K, Svergun DI. Macromolecular HPMA-based nanoparticles with cholesterol for solid-tumor targeting: detailed study of the inner structure of a highly efficient drug delivery system. Biomacromolecules. 13: 2594-604. PMID 22793269 DOI: 10.1021/bm3008555 |
0.633 |
|
| 2011 |
Etrych T, Kovář L, Strohalm J, Chytil P, Ríhová B, Ulbrich K. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy. Journal of Controlled Release : Official Journal of the Controlled Release Society. 154: 241-8. PMID 21699933 DOI: 10.1016/j.jconrel.2011.06.015 |
0.762 |
|
| 2011 |
Etrych T, Strohalm J, Chytil P, Černoch P, Starovoytova L, Pechar M, Ulbrich K. Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 42: 527-39. PMID 21392579 DOI: 10.1016/j.ejps.2011.03.001 |
0.739 |
|
| 2010 |
Chytil P, Etrych T, Kříž J, Subr V, Ulbrich K. N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 41: 473-82. PMID 20696244 DOI: 10.1016/j.ejps.2010.08.003 |
0.718 |
|
| 2010 |
Kovar L, Etrych T, Kabesova M, Subr V, Vetvicka D, Hovorka O, Strohalm J, Sklenar J, Chytil P, Ulbrich K, Rihova B. Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells Tumor Biology. 31: 233-242. PMID 20556593 DOI: 10.1007/s13277-010-0019-7 |
0.572 |
|
| 2010 |
Sirova M, Mrkvan T, Etrych T, Chytil P, Rossmann P, Ibrahimova M, Kovar L, Ulbrich K, Rihova B. Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: Efficacy, safety, and immunomodulating activity in murine model Pharmaceutical Research. 27: 200-208. PMID 19894105 DOI: 10.1007/s11095-009-9999-7 |
0.709 |
|
| 2008 |
Etrych T, Chytil P, Mrkvan T, Sírová M, Ríhová B, Ulbrich K. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. Journal of Controlled Release : Official Journal of the Controlled Release Society. 132: 184-92. PMID 18534705 DOI: 10.1016/j.jconrel.2008.04.017 |
0.72 |
|
| 2007 |
Kovár L, Strohalm J, Chytil P, Mrkvan T, Kovár M, Hovorka O, Ulbrich K, Ríhová B. The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line. Bioconjugate Chemistry. 18: 894-902. PMID 17402705 DOI: 10.1021/bc060246e |
0.63 |
|
| 2006 |
Chytil P, Etrych T, Konák C, Sírová M, Mrkvan T, Ríhová B, Ulbrich K. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification. Journal of Controlled Release : Official Journal of the Controlled Release Society. 115: 26-36. PMID 16899320 DOI: 10.1016/j.jconrel.2006.06.028 |
0.717 |
|
| 2005 |
Mrkvan T, Sirova M, Etrych T, Chytil P, Strohalm J, Plocova D, Ulbrich K, Rihova B. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity. Journal of Controlled Release : Official Journal of the Controlled Release Society. 110: 119-29. PMID 16269198 DOI: 10.1016/j.jconrel.2005.09.028 |
0.705 |
|
| Show low-probability matches. |